Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric Ligands.

Hsp90 is a molecular chaperone of pivotal importance for multiple cell pathways. ATP-regulated internal dynamics are critical for its function and current pharmacological approaches block the chaperone with ATP-competitive inhibitors. Herein, a general approach to perturb Hsp90 through design of new allosteric ligands aimed at modulating its functional dynamics is proposed. Based on the characterization of a first set of 2-phenylbenzofurans showing stimulatory effects on Hsp90 ATPase and conformational dynamics, new ligands were developed that activate Hsp90 by targeting an allosteric site, located 65 Å from the active site. Specifically, analysis of protein responses to first-generation activators was exploited to guide the design of novel derivatives with improved ability to stimulate ATP hydrolysis. The molecules' effects on Hsp90 enzymatic, conformational, co-chaperone and client-binding properties were characterized through biochemical, biophysical and cellular approaches. These designed probes act as allosteric activators of the chaperone and affect the viability of cancer cell lines for which proper functioning of Hsp90 is necessary.

[1]  David A Agard,et al.  Conformational dynamics of the molecular chaperone Hsp90 , 2011, Quarterly Reviews of Biophysics.

[2]  Lila M. Gierasch,et al.  Sending Signals Dynamically , 2009, Science.

[3]  Martin Hessling,et al.  Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90 , 2009, Nature Structural &Molecular Biology.

[4]  Giorgio Colombo,et al.  Modeling Signal Propagation Mechanisms and Ligand-Based Conformational Dynamics of the Hsp90 Molecular Chaperone Full-Length Dimer , 2009, PLoS Comput. Biol..

[5]  G. Giannini,et al.  Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold. , 2014, Journal of medicinal chemistry.

[6]  David A Agard,et al.  Species-dependent ensembles of conserved conformational states define the Hsp90 chaperone ATPase cycle. , 2008, Molecular cell.

[7]  D. Agard,et al.  Glucocorticoid Receptor Function Regulated by Coordinated Action of the Hsp90 and Hsp70 Chaperone Cycles , 2014, Cell.

[8]  Giorgio Colombo,et al.  Corresponding Functional Dynamics across the Hsp90 Chaperone Family: Insights from a Multiscale Analysis of MD Simulations , 2012, PLoS Comput. Biol..

[9]  Elisabetta Moroni,et al.  The Dynamics of Drug Discovery. , 2015, Current topics in medicinal chemistry.

[10]  S. Jackson.  Hsp90: structure and function. , 2012, Topics in current chemistry.

[11]  Susan Lindquist,et al.  Hsp90 and Environmental Stress Transform the Adaptive Value of Natural Genetic Variation , 2010, Science.

[12]  J. Reinstein,et al.  Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle , 2013, Nature Structural &Molecular Biology.

[13]  Randal D Goff,et al.  Neoglycosylation and neoglycorandomization: Enabling tools for the discovery of novel glycosylated bioactive probes and early stage leads. , 2014, MedChemComm.

[14]  Pablo C. Echeverría,et al.  An Interaction Network Predicted from Public Data as a Discovery Tool: Application to the Hsp90 Molecular Chaperone Machine , 2011, PloS one.

[15]  M. Daidone,et al.  Survivin is Highly Expressed and Promotes Cell Survival in Malignant Peritoneal Mesothelioma , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[16]  D. Agard,et al.  Substrate binding drives large-scale conformational changes in the Hsp90 molecular chaperone. , 2011, Molecular cell.

[17]  R. Groszmann,et al.  Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. , 1999, American journal of physiology. Gastrointestinal and liver physiology.

[18]  Susan Lindquist,et al.  Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition , 2012, Cell.

[19]  G. Colombo,et al.  Identification of a new scaffold for hsp90 C-terminal inhibition. , 2014, ACS medicinal chemistry letters.

[20]  L. Pearl,et al.  Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.

[21]  Gennady Verkhivker,et al.  Dynamics-Based Discovery of Allosteric Inhibitors: Selection of New Ligands for the C-terminal Domain of Hsp90. , 2010, Journal of chemical theory and computation.

[22]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[23]  Wenjie Luo,et al.  Heat shock protein 90 in neurodegenerative diseases , 2010, Molecular Neurodegeneration.

[24]  Zhizhou Fang,et al.  Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features. , 2013, ACS chemical biology.

[25]  A. Bernardi,et al.  Synthesis of potential allosteric modulators of Hsp90 by chemical glycosylation of Eupomatenoid-6. , 2014, Carbohydrate research.

[26]  B. Blagg,et al.  Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. , 2011, Journal of medicinal chemistry.

[27]  D. Bolon,et al.  Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors. , 2013 .

[28]  S. Jackson,et al.  Stimulation of the weak ATPase activity of human hsp90 by a client protein. , 2002, Journal of molecular biology.

[29]  Céline Hernandez,et al.  Dynamic Impacts of the Inhibition of the Molecular Chaperone Hsp90 on the T-Cell Proteome Have Implications for Anti-Cancer Therapy , 2013, PloS one.

[30]  J. Zorn,et al.  Turning enzymes ON with small molecules. , 2010, Nature chemical biology.

[31]  L. Pearl,et al.  Crystal structure of an Hsp90–nucleotide–p23/Sba1 closed chaperone complex , 2006, Nature.

[32]  Paul Workman,et al.  Drugging the Cancer Chaperone HSP90 , 2007, Annals of the New York Academy of Sciences.

[33]  David A. Agard,et al.  Structural Analysis of E. coli hsp90 Reveals Dramatic Nucleotide-Dependent Conformational Rearrangements , 2006, Cell.

[34]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[35]  Maulik R. Patel,et al.  Identification of an allosteric pocket on human hsp70 reveals a mode of inhibition of this therapeutically important protein. , 2013, Chemistry & biology.

[36]  J. Buchner,et al.  Artificial accelerators of the molecular chaperone Hsp90 facilitate rate-limiting conformational transitions. , 2014, Angewandte Chemie.

[37]  W. Stetler-Stevenson,et al.  Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors. , 2014, Molecular cell.

[38]  Jill L. Johnson,et al.  Hsp90 and co-chaperones twist the functions of diverse client proteins. , 2010, Biopolymers.

[39]  J. Buchner,et al.  Asymmetric activation of the hsp90 dimer by its cochaperone aha1. , 2010, Molecular cell.

[40]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[41]  L. Pearl,et al.  ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo , 1998, The EMBO journal.

[42]  J. Buchner,et al.  Structure, Function and Regulation of the Hsp90 Machinery , 2013, Biomedical journal.

[43]  Elisabetta Moroni,et al.  3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues. , 2013, ACS medicinal chemistry letters.

[44]  Cody J. Wenthur,et al.  Drugs for allosteric sites on receptors. , 2014, Annual review of pharmacology and toxicology.

[45]  Vincent J Hilser,et al.  An Ensemble View of Allostery , 2010, Science.

[46]  R. Nussinov,et al.  Allostery in Disease and in Drug Discovery , 2013, Cell.

[47]  G. Fischer,et al.  Aktivatoren des molekularen Chaperons Hsp90 erleichtern geschwindigkeitsbestimmende Konformationsänderungen , 2014 .

[48]  L. Whitesell,et al.  The stress response: implications for the clinical development of hsp90 inhibitors. , 2003, Current cancer drug targets.

[49]  Martin Hessling,et al.  The large conformational changes of Hsp90 are only weakly coupled to ATP hydrolysis , 2009, Nature Structural &Molecular Biology.

[50]  D. Agard,et al.  Uncovering a region of heat shock protein 90 important for client binding in E. coli and chaperone function in yeast. , 2013, Molecular cell.

[51]  D. Elnatan,et al.  Structural asymmetry in the closed state of mitochondrial Hsp90 (TRAP1) supports a two-step ATP hydrolysis mechanism. , 2014, Molecular cell.

[52]  D. Bolon,et al.  Enforced N-domain Proximity Stimulates Hsp90 ATPase Activity and Is Compatible with Function in Vivo* , 2011, The Journal of Biological Chemistry.

[53]  S. Lindquist,et al.  HSP90 at the hub of protein homeostasis: emerging mechanistic insights , 2010, Nature Reviews Molecular Cell Biology.

[54]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[55]  D. Elnatan,et al.  A novel N-terminal extension in mitochondrial TRAP1 serves as a thermal regulator of chaperone activity , 2014, eLife.

[56]  Maria Laura Bolognesi,et al.  Docking Ligands on Protein Surfaces: The Case Study of Prion Protein. , 2009, Journal of chemical theory and computation.

[57]  R. Immormino,et al.  Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. , 2007, Molecular cell.